Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
- PMID: 37773550
- PMCID: PMC10541350
- DOI: 10.1186/s13613-023-01194-x
Correction: Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial
Erratum for
-
Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial.Ann Intensive Care. 2023 Aug 27;13(1):75. doi: 10.1186/s13613-023-01168-z. Ann Intensive Care. 2023. PMID: 37634234 Free PMC article.
References
-
- Chevret S, Bouadma L, Dupuis C, Burdet C, Timsit J-F, the COVIDICUS RCT group Which severe COVID-19 patients could benefit from high dose dexamethasone? A Bayesian post-hoc reanalysis of the COVIDICUS randomized clinical trial. Ann Intensive Care. 2023;13:75. doi: 10.1186/s13613-023-01168-z. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
